To include your compound in the COVID-19 Resource Center, submit it here.

Biogen reports Phase Ib extension data for aducanumab in AD

Biogen Inc. (NASDAQ:BIIB) reported 24- and 36-month data from a long-term extension of the Phase Ib PRIME trial to treat prodromal or mild Alzheimer’s disease showing that aducanumab (BIIB037) continued to reduce amyloid plaque levels, and, according to the company, suggest a continued benefit on the rate of cognitive decline, especially at the highest doses of aducanumab compared to

Read the full 598 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE